The Justice Department reported that Signal Diagnostics agreed to pay more than $20 million to resolve False Claims Act allegations tied to the HRSA Uninsured Program. According to the press-release listing, the allegations involved failure to refund overpayments, underscoring that healthcare entities can face major liability not only for initial billing conduct but also for retaining government funds after identifying overpayments. The matter reflects continuing federal attention to pandemic-era reimbursement programs and repayment obligations.
